title: Pretransplant soluble CD30 serum concentration does not affect kidney graft outcomes 3 years after transplantation.
abstract: BACKGROUND
  An elevated serum concentration of soluble the form of CD30 (sCD30), an activation marker of mainly T(H)2-type cytokines producing T lymphocytes, has been reported as a predictive factor for acute cellular rejection episodes and poor graft outcomes in kidney transplantation. This historic cohort study investigated the association of a pretransplant sCD30 serum concentrations with kidney graft function and graft survival 3 years posttransplantation in adult recipients of deceased donor kidney grafts, treated with monoclonal anti-CD25 antibodies as an induction treatment combined with a cyclosporine (CsA)-based maintenance triple therapy.
  
  
  METHODS
  The pretransplant sera of 296 recipients were tested for sCD30 content using a microsphere flow-cytometry assay. The estimated glomerular filtration rate (eGFR) was determined by the 4-variable Modification of Diet in Renal Disease equation. The incidences of graft loss were calculated with the use of Kaplan-Meier survival analysis and compared using the log-rank test.
  
  
  RESULTS
  According to the distribution of the pretransplant sCD30 levels concentration ≥2700 pg/mL was defined as high (n = 146) and concentration <2700 pg/mL as low (n = 150). Three years posttransplantation, the eGFR was not significantly different in the recipients in high and low sCD30 groups (65 ± 24 vs 67 ± 21 mL/min/1.73 m(2); P = .43); there was no association between the eGFR 3 years after transplantation and the pretransplant sCD30 levels (r(2) = 0.002; P = .49). Graft survival 3 years after transplantation was also not different in the recipients in high and low sCD30 groups (P = .52).
  
  
  CONCLUSIONS
  In our adult deceased-donor kidney graft recipients, the pretransplant sCD30 serum concentration was not a predictive factor of immunologic risk associated with the kidney graft function 3 years posttransplantation; neither did it affect graft survival 3 years after transplantation. The immunosuppression with anti-CD25 antibodies as an induction treatment combined with the CsA-based maintenance triple therapy could possibly be decisive for our findings.
authors.affiliation: Department of Nephrology, University Medical Center, Ljubljana, Slovenia. janko.kovac@kclj.si
authors.forename: J
authors.initials: J
authors.lastname: Kovač
authors.forename: M
authors.initials: M
authors.lastname: Arnol
authors.forename: B
authors.initials: B
authors.lastname: Vidan Jeras
authors.forename: A F
authors.initials: AF
authors.lastname: Bren
authors.forename: A
authors.initials: A
authors.lastname: Kandus
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D015331:Cohort Studies; D016572:Cyclosporine / Q000008:administration & dosage; D005260:Female; D005434:Flow Cytometry; D005919:Glomerular Filtration Rate; D006085:Graft Survival; D006801:Humans; D017730:Ki-1 Antigen / Q000097:blood*; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis
chemical_list: D000911:Antibodies, Monoclonal; D017730:Ki-1 Antigen; D016572:Cyclosporine